Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma

Richard J. Santen, Andrea Manni, Harold Harvey

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

'Superagonist' analogs of GnRH produce a paradoxical inhibition of gonadotropin secretion when given on a long-term basis, and may well produce a more complete 'medical oophorectomy' than antiestrogens in premenopausal breast cancer patients. Here we review the background and pharmacology of these agents, together with the experience of their use with prostate cancer and early trials in breast cancer. Their effectiveness without significant toxicity, together with new biodegradable implants for their easily acceptable long-term administration, suggest that a highly selective medical means of fully inhibiting ovarian estrogen production is now available for more extensive trials in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)129-145
Number of pages17
JournalBreast Cancer Research and Treatment
Volume7
Issue number3
DOIs
StatePublished - Oct 1 1986

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma'. Together they form a unique fingerprint.

Cite this